Low Dose Naltrexone: Motility Effects Leonard Weinstock, MD.

Slides:



Advertisements
Similar presentations
Gastro-intestinal Physiology General Prof. K. Sivapalan.
Advertisements

1 IV MOTILITY OF THE SMALL INTESTINE 2 Function of Intestinal Motility (1)To mix chyme with digestive secretion (2)To bring fresh chyme into contact.
Smooth muscle surrounds the major hollow organs - including: blood vessels, bronchi, gut, uterus, bladder. Responsive to a variety of stimuli: neural input.
GASTROINTESTINAL PHYSIOLOGY Chapter-III (Gastrointestinal Motility) Ass. Prof. Dr. Emre Hamurtekin EMU Faculty of Pharmacy.
Regulation of Gastric Emptying
IV MOTILITY OF THE SMALL INTESTINE
Diarrhoea and Constipation By Priyanca Patel. What is Constipation? Infrequent bowel movements due to increased transit time or pelvic dysfunction What.
Lecture 3 Dr. Zahoor Ali Shaikh
Gastroparesis Diagnosis and Treatment
CMOA HT 4 Receptor Physiology and Pharmacodynamic Effects of Tegaserod Michael Camilleri, MD Gastroenterology Research Unit Mayo Clinic Foundation.
Human Anatomy and Physiology Transport and mixing of food in the alimentary tract.
Chapter 9: Opioid Analgesics
The digestive tract plays a role of bringing life sustaining elements into the body and taking waste products out of it.
Digestive Disorders Lesson 2. Constipation Infrequent bowel movements Stools are dry, small and difficult to eliminate Can be caused by –inadequate water.
Drug presentation 1 agonist/antagonist Barry Barkinsky EMS-I, Paramedic.
CI-1 Zelnorm ® (tegaserod maleate) Gastrointestinal Drugs Advisory Committee Meeting July 14, 2004 Gastrointestinal Drugs Advisory Committee Meeting July.
1 III GASTRIC MOTILITY. 2 Major Function of Gastric Motility  To serve as a reservoir  To break food into small particles and mix food with gastric.
Digestive System.
1. What is the most common cause of constipation? A.Pelvic floor dyssynergia B.Slow transit C.Functional D.Mechanical obstruction.
IN 1 NDA Gastrointestinal Advisory Committee Meeting Gaithersburg, Maryland June 26, 2000 Gastrointestinal Advisory Committee Meeting Gaithersburg,
Procainamide Derivative- Metoclopramide *Reglan Blocks receptors in the CRTZ. Prokinetic drug: increases gastric contractions and speeds emptying, strengthens.
The physiological and pathophysiological roles of the Urocortins Krisztina Kárpáti and Hélène Rivière JPEMS
Aging & the Gastrointestinal System
Regulation of the Digestive System The digestive system is regulated by the nervous and endocrine systems – Nervous System In the presence of food, a message.
STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.
Gastrointestinal physiology 1 M.Bayat Ph.D GI tract motility.
Laxatives and Antidiarrheals
Buprenorphine {Suboxone®, Subutex®}
1 III GASTRIC MOTILITY. 2 Major Function of Gastric Motility  To serve as a reservoir  To break food into small particles and mix food with gastric.
The Endocrine System Overview GR 10 A. Endocrine Organs Endocrine system is series of organs and glands in body that secrete chemical messengers into.
Understand the functions of the digestive system 2.08 Understand the functions and disorders of the digestive system2.
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
Low Dose Naltrexone and Complex Regional Pain Syndrome Leonard Weinstock, MD Associate Professor of Clinical Medicine Washington University in St. Louis.
New Use for LDN: Sarcoidosis Leonard Weinstock, MD Associate Professor of Clinical Medicine Washington University School of Medicine President, Specialists.
LDN for Autoimmune and Inflammatory Diseases Leonard Weinstock, MD Associate Professor of Clinical Medicine Washington University School of Medicine President,
Turn in Problem set 4 Friday UNIT FIVE. Review: What is a monoamine? 1.A metabolic enzyme 2.A molecule with a CH 3 group on it 3.A molecule with an NH.
Digestive system Gastroenterology.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions?
Movements of the small intestine
Managing the Itch Alok Vij, MD Department of Dermatology
Low Dose Naltrexone Mechanisms of Action and Clinical Applications
Body Basics Chapter 03.
Pathophysiology of irritable bowel syndrome
Drugs.
Antidiarrheal agents Domina Petric, MD.
Nikki Delgado and Joy Hochstetler
Drugs for the treatment of irritable bowel syndrome (IBS)
Management of the irritable bowel syndrome
Medication-Assisted Treatment 101: Breaking the Stigma
Orphanin FQ, but not dynorphin A, accelerates colonic transit in rats
Jonathan Moss, MD, PhD, Carl E. Rosow, MD, PhD  Mayo Clinic Proceedings 
About Plasma and intestinal concentrations of sulfadiazine-trimethoprim in pigs after (non)conventional oral and intramuscular treatment, within the context.
Volume 142, Issue 4, Pages e4 (April 2012)
Volume 131, Issue 1, Pages (July 2006)
Digestive System: Outcome: I can describe different digestive hormones used in the chemical breakdown of food. Drill: Which digestive system disorder is.
David M. S. Grunkemeier, Joseph E. Cassara, Christine B
Gastro-intestinal Physiology General
Volume 122, Issue 2, Pages (February 2002)
Drug antagonism Lab 7 Dr. Raz Mohammed
GLP-1 Agonists and DPP-4 Inhibitors How do they work?
Volume 122, Issue 2, Pages (February 2002)
Pain Management Ahmad Abudayyeh.
School of Pharmacy, University of Nizwa
School of Pharmacy, University of Nizwa
GLP-1 Agonists and DPP-4 Inhibitors How do they work?
Lecture 2b- 17 January 2019 Lecture based largely on chapter 1 of
Gastrointestinal Physiology
Physiology Lecture: 46 Gastrointestinal Physiology
Douglas C. McVey, Steven R. Vigna  Gastroenterology 
Hapten-Specific Tolerance Promoted by Calcitonin Gene-Related Peptide
Presentation transcript:

Low Dose Naltrexone: Motility Effects Leonard Weinstock, MD

Disclosures  Speakers Bureaus  Salix  Entera Health  Forrest  Off label use of medications

Low Dose Naltrexone: Motility Effects Unexpected effect on endorphins by being an opioid blocker Motility effects of endorphins, short-acting narcotics and naltrexone are counterintuitive

Topics Brief Review of LDN Brief Review of LDN Opioid Receptors and Functions Opioid Receptors and Functions Opioids and Endorphins on MMC (important for SIBO) Opioids and Endorphins on MMC (important for SIBO) Anti-opiates in Humans in Constipation Anti-opiates in Humans in Constipation

LDN: mechanism of action  LDN displaces endorphins from opioid receptors for 4 hours  Cells sense opioid deficiency and rebound via a positive feedback mechanism  Receptors increased  Met-enkephalin production x fold

Endorphins: Functions  Regulate cell growth  Decrease inflammation  Decrease vascular permeability  Stabilize Toll-like receptors  Decrease microglia activation (reduce pain)  Decrease cytokine release  Shift from TH2 to TH1 immunity  Motility effects – ?

Opioid Receptors in GI Tract Activation slows motility by continuous contraction Activation causes constipation by increased absorption and decreased secretion

Endogenous Opioid Activity and Constipation

Opioid Receptors Experimental inflammation in mice: Experimental inflammation in mice: Increase gut μ-opioid receptors Increase gut μ-opioid receptors Enhances potency of opioids to slow GI transit Enhances potency of opioids to slow GI transit Abdominal surgery leads increase in endomorphin in humans Abdominal surgery leads increase in endomorphin in humans Opioid receptor antagonists normalize pathologic inhibition of gut function that arises from opioid upregulation and/or over- activity Opioid receptor antagonists normalize pathologic inhibition of gut function that arises from opioid upregulation and/or over- activity Holzer. Regul Pept 2009;155:11.

Endogenous Opioids Thought to play a role in the fine tuning of digestion Thought to play a role in the fine tuning of digestion Endogenous opioid peptides participate in neural control of peristalsis by dampening peristaltic performance via activation of mu and kappa receptors Endogenous opioid peptides participate in neural control of peristalsis by dampening peristaltic performance via activation of mu and kappa receptors Distention-evoked peristalsis can be facilitated by naloxone in 4 animal models Distention-evoked peristalsis can be facilitated by naloxone in 4 animal models Holzer, P. Regul Pept 2009; 155: 11–17.

Morphine and MMC - Dogs In normal fasted dogs, morphine initiated phase III of the MMC in the duodenum which propagated distally In normal fasted dogs, morphine initiated phase III of the MMC in the duodenum which propagated distally This effect of morphine was blocked by the opioid receptor antagonists naloxone This effect of morphine was blocked by the opioid receptor antagonists naloxone Telford. Am J Physiol 1985;249:G557.

Morphine and MMC: Man Healthy subjects given MS (100 mcg/kg IV bolus) Healthy subjects given MS (100 mcg/kg IV bolus) Stimulated migrating bursts of phasic activity (similar to phase III of MMC) Stimulated migrating bursts of phasic activity (similar to phase III of MMC) Morphine stimulated ileal flow Morphine stimulated ileal flow Borody. Gastroenterology 1985;89:562.

Endorphins and MMC: Chickens Phase III of MMC studied in chickens Phase III of MMC studied in chickens EMG study in stomach and entire small intestine EMG study in stomach and entire small intestine Met-enkephalin infused i.v. Met-enkephalin infused i.v. Triggered an intestinal migrating activity concurrent with gastric inhibition Triggered an intestinal migrating activity concurrent with gastric inhibition Migrating activity started in distal duodenum and propagated to ileum - effects partially blocked by naloxone Migrating activity started in distal duodenum and propagated to ileum - effects partially blocked by naloxone Jimenez. Life Sci 1992;50:465. ?

Enkephalin and MMC: Man Met-enkephalin analogue studied in 17 humans Met-enkephalin analogue studied in 17 humans M-E induced a premature phase III of the MMC starting in the duodenum that migrated distally at a significantly higher velocity than a spontaneous phase III (potential role for LDN) M-E induced a premature phase III of the MMC starting in the duodenum that migrated distally at a significantly higher velocity than a spontaneous phase III (potential role for LDN) Their theory: M-E induced an inhibition of the inhibitory nervous system Their theory: M-E induced an inhibition of the inhibitory nervous system Jians et al. Gastroenterology1987;93: – “fine tuning” – “fine tuning”

Methyl-Naltrexone: opioid naive Compared effects of MNTX in naïve vs. opiate chronically treated guinea pigs MNTX blocked the inhibitory effect of acute morphine at any dose MNTX did not affect GI transit in naïve guinea pigs when administered acutely or for five consecutive days Anselmi, et al. Naunyn Schmiedebergs Arch Pharmacol 2013;386:279.

Methyl-Naltrexone: opioid naive MNTX twice daily for 4 days and MNTX twice daily for 4 days and MNTX plus morphine for 6 days in horses MNTX plus morphine for 6 days in horses Frequency of BM, weight of feces, moisture of feces content, intestinal transit time Frequency of BM, weight of feces, moisture of feces content, intestinal transit time MNTX increased daily fecal weight in both groups MNTX increased daily fecal weight in both groups MNTX partially prevented the effects of morphine on all four scores MNTX partially prevented the effects of morphine on all four scores Boscan. Am J Vet Res 2006;67:998.

Naloxone and CIC: Case Reports Two pts with CIC requiring high dose laxatives were treated with naloxone (single-blind crossover basis) Two pts with CIC requiring high dose laxatives were treated with naloxone (single-blind crossover basis) Both responded to naloxone - increased frequency and weight of BM Both responded to naloxone - increased frequency and weight of BM Positive response with oral and IV: Positive response with oral and IV: Primary effect of naloxone is at receptor sites in the myenteric plexus and other neural and endocrine cells of the intestinal wall Primary effect of naloxone is at receptor sites in the myenteric plexus and other neural and endocrine cells of the intestinal wall Kreek et al. Lancet 1983;1:261.

LDN and Chronic Constipation (my observations) N=12; Open-label Rx 2.5 mg twice a day N=12; Open-label Rx 2.5 mg twice a day 58% markedly improved 58% markedly improved 1% moderately improved 1% moderately improved 25% mildly improve 25% mildly improve 1% unchanged 1% unchanged Subsequently – approximately 20 more pts are maintained on LDN for constipation Subsequently – approximately 20 more pts are maintained on LDN for constipation Ploesser J, Weinstock LB, Thomas E. Internat J Pharm Compound 2010:

High Dose Naltrexone in IBS-c Study of tegaserod alone and combined with naltrexone 50 mg on intestinal transit and stool characteristics in females with IBS-c N = 48 randomized to tegaserod alone, naltrexone alone or in combination with tegaserod or placebo for 6 days. Small bowel and colon studied by nuclear testing Tegaserod increased small bowel and colon transit Naltrexone did not accelerate colonic transit relative to placebo Combination treatment did not significantly accelerate transit relative to tegaserod alone Foxx-Orenstein et al. Neurogastroenterol Motil 2007;19:821.

Naltrexone  Improve GI motility – via fine tune blocking endogenous opioids?  Prevent SIBO by increasing endorphins which increase MMC?  Reduce inflammation with a secondary effect of normalizing motility?  Reduce pain of IBS via Toll-receptor activity and allow for better motility?